• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Glytec launches new insulin management system

March 30, 2021 By Sean Whooley

GlytecGlytec announced today that it introduced the latest version of its eGlycemic Management System (eGMS) for managing insulin.

Waltham, Mass.-based Glytec’s eGMS is centered around the FDA-cleared Glucommander algorithm, which leverages real-time and historical data to recommend insulin dosing by learning each patient’s insulin sensitivity and anticipating future needs, leading to a personalized treatment regime that can reduce hypoglycemia, hyperglycemia, lengths of stay, readmissions and cost of care, according to a news release.

Enhancements to the latest version of the eGMS software platform include ways to reduce workflow friction for clinicians and further improve patient safety, Glytec siad.

Order set initiation allows for the Glucommander to automatically receive initial parameters as ordered by the provider, while medication dose confirmation sees data sent to the EMR flowsheet and displayed in the medication administration record so a nurse can view and chart the administration of the dose before sending information back to the Glucommander to confirm the actual dose that was given.

Additionally, the new enhancements allow for Glucommander SubQ, which leverages the laboratory interfaces to recover overnight blood glucose (BG) values that were not entered, leading to more effective and safter insulin dosing recommendations.

Finally, the upgrades include Meter Max override, which builds on the existing Meter Max feature of the Glucommander and allows for nurses to start insulin treatment without waiting for lab values.

“For the past 15 years, Glytec has been at the forefront of developing computer-guided algorithms that make personalized insulin dosing possible. These latest enhancements are just the most recent example of our ongoing commitment to patient safety and improving nursing workflows. Our 3.5.1.0 release includes many enhancements that we can directly attribute to feedback we’ve received by carefully listening to the doctors, nurses, pharmacists and administrators at hospitals across the country who use our platform,” Glytec CCO John Downey said in the release. “With evidence indicating a strong association between timely and accurate glucose management, improved outcomes and lower costs we are finding that health systems are already showing an increasing interest in Glucommander. With these important new innovations, we expect that adoption will expand even more rapidly.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Hospital Care, Patient Monitoring Tagged With: Glytec

IN CASE YOU MISSED IT

  • Another BD Alaris infusion pump recall is Class I
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
  • Horizon touts data from trials for thyroid eye disease infusion treatment
  • Genentech touts study results for spinal muscular atrophy drug in babies

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS